Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma

US Patent 6682734 · Granted Jan 27, 2004

Estimated economic value: $115,892,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Drug conjugates of cMET monoclonal binding agents, and uses thereof2024
CMET monoclonal binding agents, drug conjugates thereof and uses thereof2022
Syndecan-1 (CD138) binding agents and uses thereof2022
Antibody-fynomer conjugates2019
Modified binding molecules comprising connecting peptides2013
Expression and use of anti-CD20 Antibodies2010
Expression and use of anti-CD20 Antibodies2010
Expression and use of anti-CD20 Antibodies2010
Expression and use of anti-CD20 Antibodies2010
Expression and use of anti-CD20 Antibodies2010
Expression and use of anti-CD20 Antibodies2010
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as the2010